Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(25)00401-2
Affiliations:
13
Authors:
14
Go to article
Institutions Authors Share
Roche R&D Center (China) Ltd., China
4.000000
 0.29
Genentech, Inc., United States of America (USA)
1.500000
 0.11
National Taiwan University Hospital (NTUH), Taiwan
1.000000
 0.07
Zhongshan Hospital, Fudan University, China
1.000000
 0.07
Beijing Cancer Hospital / School of Oncology, PKUHSC, China
1.000000
 0.07
Affiliated Hospital of Jining Medical University, China
1.000000
 0.07
Samsung Medical Center (SMC), South Korea
1.000000
 0.07
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, China
1.000000
 0.07
First Affiliated Hospital, ZZU, China
1.000000
 0.07
The First Affiliated Hospital of Henan University of Science and Technology, China
1.000000
 0.07
Gilead, United States of America (USA)
0.500000
 0.04
Interested in Oncology and Carcinogenesis?